Compounds > enciprazine
Page last updated: 2024-12-06

enciprazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Enciprazine is a novel, orally active, selective, and potent inhibitor of the enzyme phosphodiesterase 4B (PDE4B). It is currently in clinical development for the treatment of major depressive disorder (MDD) and other CNS disorders. Preclinical studies have shown that enciprazine has antidepressant-like effects in animal models of depression, and it is thought to exert its therapeutic effects by increasing the levels of the neurotransmitter cyclic adenosine monophosphate (cAMP) in the brain. PDE4B is highly expressed in brain regions involved in mood regulation, and its inhibition has been shown to improve cognitive function and reduce inflammation, which may contribute to the antidepressant effects of enciprazine. In clinical trials, enciprazine has been shown to be well-tolerated and to have a rapid onset of antidepressant effects. Enciprazine is being studied as a potential treatment for MDD, as well as for other CNS disorders, such as anxiety disorders, Alzheimer's disease, and Parkinson's disease.'

enciprazine: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID50222
CHEMBL ID101284
SCHEMBL ID584730
MeSH IDM0160246

Synonyms (29)

Synonym
d-13112
enciprazine
CHEMBL101284
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenoxy)propan-2-ol
68576-86-3
enciprazino [inn-spanish]
enciprazine [inn:ban]
unii-l6x660925g
l6x660925g ,
enciprazinum [inn-latin]
1-piperazineethanol, 4-(2-methoxyphenyl)-alpha-((3,4,5-trimethoxyphenoxy)methyl)-, (+-)-
enciprazino
enciprazinum
AKOS015994665
1-piperazineethanol, 4-(2-methoxyphenyl)-.alpha.-((3,4,5-trimethoxyphenoxy)methyl)-, (+/-)-
enciprazine [inn]
enciprazine [mi]
(+/-)-1-(3-(3,4,5-trimethoxyphenoxy)-2-hydroxypropyl)-4-(2-methoxyphenyl)piperazine
4-(2-methoxyphenyl)-a-((3,4,5-trimethoxyphenoxy)methyl)-1-piperazineethanol
(+/-)-4-(o-methoxyphenyl)-.alpha.-((3,4,5-trimethoxyphenoxy)methyl)-1-piperazineethanol
SCHEMBL584730
cas-68576-86-3
dtxsid3057806 ,
NCGC00253761-01
tox21_113874
dtxcid1031595
KE-0221
Q27282790
1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(3,4,5-trimethoxyphenoxy)propan-2-ol

Research Excerpts

Overview

Enciprazine is a propanolamine derivative with a preclinical profile similar to buspirone but with less affinity for the postsynaptic dopamine receptor.

ExcerptReferenceRelevance
"Enciprazine is a propanolamine derivative with a preclinical profile similar to buspirone but with less affinity for the postsynaptic dopamine receptor (Linden et al. "( A placebo-controlled study of enciprazine in the treatment of generalized anxiety disorder: a preliminary report.
Csanalosi, I; London, J; Rickels, K; Schweizer, E; Turner, D, 1990)		2.01

Dosage Studied

ExcerptRelevanceReference
" dosing to rats and dogs."( Metabolic disposition of enciprazine, a non-benzodiazepine anxiolytic drug, in rat, dog and man.
Cayen, MN; Lockhead, SR; Scatina, JA; Sisenwine, SF, 1991)		0.58
"The new basic propanolamine derivative enciprazine (D 13 112) was tested in an open single-blind phase-II trial with regard to therapeutic efficacy, clinical safety, and dosage finding."( Pilot study on the therapeutic efficacy, clinical safety, and dosage finding of enciprazine in out-patients with anxious and anxious-depressive syndromes.
Buchheim, P; Grohmann, R; Scheibe, G, 1990)		0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.37100.001022.650876.6163AID1224838
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency34.67130.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency27.54040.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (65)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID179310Effect on restlessness after oral administration of 50 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127465Tested for ability to maintain self-administration after administration of 0.3 mg/kg in monkey 9079 (0-2)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127439Tested for ability to maintain self-administration after administration of 0.03 mg/kg in monkey 2037 Range (7-9)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127312Tested for ability to maintain self-administration after administration of 0.003 mg/kg in monkey 9079 Range (1-6)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127443Tested for ability to maintain self-administration after administration of 0.03 mg/kg in monkey 3038 Range (1-10)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127317Tested for ability to maintain self-administration after administration of 0.01 mg/kg in monkey 9079 Range (1-3)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179168Effect on diarrheal after oral administration of 100 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179290Effect on jumping after oral administration of 100 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127310Tested for ability to maintain self-administration after administration of 0.003 mg/kg in monkey 3017 Range (1-2)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127306Tested for ability to maintain self-administration after administration of 0.001 mg/kg in monkey 3017 Range (0-1)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179317Effect on tremor after oral administration of 100 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127313Tested for ability to maintain self-administration after administration of 0.003 mg/kg in monkey 9083 Range (13-21)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127311Tested for ability to maintain self-administration after administration of 0.003 mg/kg in monkey 3038 Range (1-7)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127440Tested for ability to maintain self-administration after administration of 0.03 mg/kg in monkey 3017 Range (1-7)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127468Tested for ability to maintain self-administration after administration of 0.3 mg/kg in monkey 9083 (1-4)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179314Effect on salivation after oral administration of 50 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127309Tested for ability to maintain self-administration after administration of 0.003 mg/kg in monkey 2037 Range (2-6)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127462Tested for ability to maintain self-administration after administration of 0.3 mg/kg in monkey 3038 (1-2)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179319Effect on tremor after oral administration of 50 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179169Effect on diarrheal after oral administration of 50 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179308Effect on restlessness after oral administration of 100 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127459Tested for ability to maintain self-administration after administration of 0.3 mg/kg in monkey 3017 (0-1)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179292Effect on jumping after oral administration of 50 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127444Tested for ability to maintain self-administration after administration of 0.03 mg/kg in monkey 9079 Range (2-24)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127471Tested for ability to maintain self-administration after administration of 1 mg/kg in monkey 9079 (0-3)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179299Effect on piloerection after oral administration of 50 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127307Tested for ability to maintain self-administration after administration of 0.001 mg/kg in monkey 3038 Range (2-5)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127457Tested for ability to maintain self-administration after administration of 0.3 mg/kg in monkey 2037 (0-4)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179297Effect on piloerection after oral administration of 100 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127446Tested for ability to maintain self-administration after administration of 0.03 mg/kg in monkey 9083 Range (7-11)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID179312Effect on salivation after oral administration of 100 mg/kg in rat was determined; '-' No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127454Tested for ability to maintain self-administration after administration of 0.3 mg/kg in monkey 2036 (1-5)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127318Tested for ability to maintain self-administration after administration of 0.03 mg/kg in monkey 2036 Range (2-3)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID127308Tested for ability to maintain self-administration after administration of 0.003 mg/kg in monkey 2036 Range (5-9)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's5 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (13.33)24.3611
2020's6 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.70 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (6.67%)4.05%
Observational0 (0.00%)0.25%
Other11 (73.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
buspirone
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.		7.6730azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
clobazam
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.		1.97101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		7.38201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
flurazepam
Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.		1.97101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		1.9710barbituratesGABAA receptor agonist
prazepam
Prazepam: A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.		1.9710benzodiazepine
corticosterone
[no description available]		1.991011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
gepirone
gepirone: RN given refers to parent cpd; structure given in first source		1.9910N-arylpiperazine
tandospirone
tandospirone: structure given in first source. tandospirone : A dicarboximide that is (3aR,4S,7R,7aS)-hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione which is substituted by a 4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl group at position 2. It is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM).		1.9910bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines		antidepressant;
anxiolytic drug
ConditionIndicatedRelationship StrengthStudiesTrials
Chemical Dependence
[description not available]		01.9710
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.		01.9710
Substance-Related Disorders
Disorders related to substance use or abuse.		01.9710
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Anxiety Neuroses
[description not available]		04.3222
Anxiety Disorders
Persistent and disabling ANXIETY.		04.3222
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		03.3611
Neuroses
[description not available]		03.3511
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		03.3511
Neurotic Disorders
Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.		03.3511